Who Buys Carfilzomib from India — 105 Importers Behind a $1.2M Market

Carfilzomib, a proteasome inhibitor used in the treatment of multiple myeloma, has been exported from India to 47 countries, involving 105 buyers across 203 shipments totaling $1.2 million. The repeat buyer rate stands at 36.2%, indicating a moderate level of recurring demand.

Buyer Segments:

1. Distributors: Entities that purchase Carfilzomib for resale to healthcare providers. For instance, ZETI PHARMACEUTICALS PHARMAZETI CIALIMITEDA in Ecuador, the top buyer with purchases totaling $0.05 million, likely operates as a distributor, supplying the drug to local hospitals and clinics.

2. Hospital Groups: Large healthcare institutions procuring directly for patient treatment. While specific hospital groups are not identified in the top buyers, it's common for such entities to source medications directly to ensure supply chain reliability.

3. Retail Chains: Pharmacy chains that stock Carfilzomib for outpatient dispensing. The data does not specify retail chains among the top buyers, suggesting that purchases are predominantly made by larger entities.

4. Government Procurement: National health agencies or international organizations like UNICEF and the Global Fund that acquire medications for public health programs. The absence of such buyers in the top 10 suggests that Carfilzomib procurement may be more decentralized or handled through other channels in these regions.

5. Re-exporters: Companies that import Carfilzomib for the purpose of exporting to other markets. RAFTAR MARIME FZE in the United Arab Emirates, with purchases totaling $0.02 million, may function as a re-exporter, leveraging the UAE's strategic position as a trade hub.

6. Contract Manufacturers: Firms that produce Carfilzomib under contract for other companies. The provided data does not indicate contract manufacturers among the top buyers, implying that Indian exporters are supplying finished products directly to end-users or distributors.

Buying Behavior and Order Patterns:

• Distributors and Re-exporters: These buyers typically place bulk orders to achieve economies of scale, ensuring a steady supply to meet market demand. Their purchasing patterns are influenced by market demand forecasts and inventory turnover rates.

• Hospital Groups: When involved, they procure based on patient needs and treatment protocols, often engaging in long-term contracts to secure consistent supply.

• Retail Chains: If present, they would order smaller quantities more frequently, aligning with prescription trends and shelf-life considerations.

• Government Procurement: Such entities usually engage in large-scale tenders, focusing on cost-effectiveness and broad population coverage.

Understanding the regulatory landscape is crucial for market entry and compliance. Below is an overview of the import regulations for Carfilzomib in the top five importing countries:

1. Russia:

• Regulatory Authority: Ministry of Health of the Russian Federation.

• Import Registration Process: Requires submission of a registration dossier, including clinical trial data, quality documentation, and labeling information.

• Estimated Timeline: Approximately 12-18 months, depending on the completeness of the submission and any additional requirements.

• Import Tariff/Duty: Pharmaceutical products under HS Code 30049049 are subject to a standard import duty; specific rates should be confirmed with the Federal Customs Service.

2. Chile:

• Regulatory Authority: Instituto de Salud Pública de Chile (ISP).

• Import Registration Process: Submission of a technical dossier, including product specifications, manufacturing details, and clinical data.

• Estimated Timeline: Approximately 6-12 months, subject to the review process and any additional information requests.

• Import Tariff/Duty: Medicines classified under HS Code 30049049 may benefit from preferential tariffs under trade agreements; verification with Chilean Customs is recommended.

3. Ecuador:

• Regulatory Authority: Agencia Nacional de Regulación, Control y Vigilancia Sanitaria (ARCSA).

• Import Registration Process: Requires a comprehensive dossier submission, including quality, safety, and efficacy data.

• Estimated Timeline: Approximately 8-14 months, depending on the evaluation process and any additional requirements.

• Import Tariff/Duty: Pharmaceutical imports under HS Code 30049049 are subject to import duties; specific rates should be confirmed with Ecuadorian Customs.

4. United Arab Emirates:

• Regulatory Authority: Ministry of Health and Prevention (MOHAP).

• Import Registration Process: Submission of a registration application, including product details, manufacturing information, and clinical data.

• Estimated Timeline: Approximately 6-9 months, subject to the review process and any additional information requests.

• Import Tariff/Duty: Pharmaceutical products under HS Code 30049049 are generally exempt from import duties; confirmation with UAE Customs is advisable.

5. Armenia:

• Regulatory Authority: Ministry of Health of the Republic of Armenia.

• Import Registration Process: Requires submission of a registration dossier, including quality, safety, and efficacy data.

• Estimated Timeline: Approximately 9-12 months, depending on the completeness of the submission and any additional requirements.

• Import Tariff/Duty: Pharmaceutical imports under HS Code 30049049 are subject to import duties; specific rates should be confirmed with Armenian Customs.

The demand for Carfilzomib in importing countries is influenced by several factors:

1. Disease Prevalence: Multiple myeloma, the primary indication for Carfilzomib, has varying prevalence rates globally. Countries with higher incidence rates exhibit greater demand for effective treatments.

2. Government Healthcare Programs: National health initiatives aimed at improving cancer care accessibility contribute to increased procurement of oncology drugs. For example, countries expanding universal health coverage are more likely to include advanced therapies like Carfilzomib in their formularies.

3. WHO Essential Medicines List (EML): Inclusion of a drug in the WHO EML can influence national procurement decisions. While Carfilzomib is not currently listed, its therapeutic significance may prompt consideration for inclusion, thereby affecting demand.

4. Tender-Based Purchasing: Many countries utilize tender systems for pharmaceutical procurement, focusing on cost-effectiveness and supply reliability. Participation in such tenders can significantly impact market opportunities for Carfilzomib suppliers.

Given the presence of 105 buyers across 47 countries, the market for Carfilzomib demonstrates a broad international reach. Targeted engagement with healthcare providers, alignment with national health priorities, and compliance with regulatory requirements are essential strategies for capitalizing on these market opportunities.

Carfilzomib, a proteasome inhibitor used in the treatment of multiple myeloma, has been exported from India to 47 countries, involving 105 buyers across 203 shipments totaling $1.2 million. The repeat buyer rate stands at 36.2%, indicating a moderate level of recurring demand.

Buyer Segments:

1. Distributors: Entities that purchase Carfilzomib for resale to healthcare providers. For instance, ZETI PHARMACEUTICALS PHARMAZETI CIALIMITEDA in Ecuador, the top buyer with purchases totaling $0.05 million, likely operates as a distributor, supplying the drug to local hospitals and clinics.

2. Hospital Groups: Large healthcare institutions procuring directly for patient treatment. While specific hospital groups are not identified in the top buyers, it's common for such entities to source medications directly to ensure supply chain reliability.

3. Retail Chains: Pharmacy chains that stock Carfilzomib for outpatient dispensing. The data does not specify retail chains among the top buyers, suggesting that purchases are predominantly made by larger entities.

4. Government Procurement: National health agencies or international organizations like UNICEF and the Global Fund that acquire medications for public health programs. The absence of such buyers in the top 10 suggests that Carfilzomib procurement may be more decentralized or handled through other channels in these regions.

5. Re-exporters: Companies that import Carfilzomib for the purpose of exporting to other markets. RAFTAR MARIME FZE in the United Arab Emirates, with purchases totaling $0.02 million, may function as a re-exporter, leveraging the UAE's strategic position as a trade hub.

6. Contract Manufacturers: Firms that produce Carfilzomib under contract for other companies. The provided data does not indicate contract manufacturers among the top buyers, implying that Indian exporters are supplying finished products directly to end-users or distributors.

Buying Behavior and Order Patterns:

• Distributors and Re-exporters: These buyers typically place bulk orders to achieve economies of scale, ensuring a steady supply to meet market demand. Their purchasing patterns are influenced by market demand forecasts and inventory turnover rates.

• Hospital Groups: When involved, they procure based on patient needs and treatment protocols, often engaging in long-term contracts to secure consistent supply.

• Retail Chains: If present, they would order smaller quantities more frequently, aligning with prescription trends and shelf-life considerations.

• Government Procurement: Such entities usually engage in large-scale tenders, focusing on cost-effectiveness and broad population coverage.

Understanding the regulatory landscape is crucial for market entry and compliance. Below is an overview of the import regulations for Carfilzomib in the top five importing countries:

1. Russia:

• Regulatory Authority: Ministry of Health of the Russian Federation.

• Import Registration Process: Requires submission of a registration dossier, including clinical trial data, quality documentation, and labeling information.

• Estimated Timeline: Approximately 12-18 months, depending on the completeness of the submission and any additional requirements.

• Import Tariff/Duty: Pharmaceutical products under HS Code 30049049 are subject to a standard import duty; specific rates should be confirmed with the Federal Customs Service.

2. Chile:

• Regulatory Authority: Instituto de Salud Pública de Chile (ISP).

• Import Registration Process: Submission of a technical dossier, including product specifications, manufacturing details, and clinical data.

• Estimated Timeline: Approximately 6-12 months, subject to the review process and any additional information requests.

• Import Tariff/Duty: Medicines classified under HS Code 30049049 may benefit from preferential tariffs under trade agreements; verification with Chilean Customs is recommended.

3. Ecuador:

• Regulatory Authority: Agencia Nacional de Regulación, Control y Vigilancia Sanitaria (ARCSA).

• Import Registration Process: Requires a comprehensive dossier submission, including quality, safety, and efficacy data.

• Estimated Timeline: Approximately 8-14 months, depending on the evaluation process and any additional requirements.

• Import Tariff/Duty: Pharmaceutical imports under HS Code 30049049 are subject to import duties; specific rates should be confirmed with Ecuadorian Customs.

4. United Arab Emirates:

• Regulatory Authority: Ministry of Health and Prevention (MOHAP).

• Import Registration Process: Submission of a registration application, including product details, manufacturing information, and clinical data.

• Estimated Timeline: Approximately 6-9 months, subject to the review process and any additional information requests.

• Import Tariff/Duty: Pharmaceutical products under HS Code 30049049 are generally exempt from import duties; confirmation with UAE Customs is advisable.

5. Armenia:

• Regulatory Authority: Ministry of Health of the Republic of Armenia.

• Import Registration Process: Requires submission of a registration dossier, including quality, safety, and efficacy data.

• Estimated Timeline: Approximately 9-12 months, depending on the completeness of the submission and any additional requirements.

• Import Tariff/Duty: Pharmaceutical imports under HS Code 30049049 are subject to import duties; specific rates should be confirmed with Armenian Customs.

The demand for Carfilzomib in importing countries is influenced by several factors:

1. Disease Prevalence: Multiple myeloma, the primary indication for Carfilzomib, has varying prevalence rates globally. Countries with higher incidence rates exhibit greater demand for effective treatments.

2. Government Healthcare Programs: National health initiatives aimed at improving cancer care accessibility contribute to increased procurement of oncology drugs. For example, countries expanding universal health coverage are more likely to include advanced therapies like Carfilzomib in their formularies.

3. WHO Essential Medicines List (EML): Inclusion of a drug in the WHO EML can influence national procurement decisions. While Carfilzomib is not currently listed, its therapeutic significance may prompt consideration for inclusion, thereby affecting demand.

4. Tender-Based Purchasing: Many countries utilize tender systems for pharmaceutical procurement, focusing on cost-effectiveness and supply reliability. Participation in such tenders can significantly impact market opportunities for Carfilzomib suppliers.

Given the presence of 105 buyers across 47 countries, the market for Carfilzomib demonstrates a broad international reach. Targeted engagement with healthcare providers, alignment with national health priorities, and compliance with regulatory requirements are essential strategies for capitalizing on these market opportunities.